20/06/2025
A Game-Changer in HIV Prevention: Twice-Yearly Shot Gets FDA Green Light 🎉
The U.S. has just approved Yeztugo (lenacapavir) — the first-ever HIV prevention shot that only needs to be taken twice a year. It’s a big step forward in making HIV prevention simpler, safer, and more accessible for everyone.
✱ What is it?
A small injection under the skin, given just once every 6 months, to protect people from getting HIV.
✱ Why is it special?
In studies with over 4,000 people, more than 99.9% stayed HIV-free. It works better than current daily pills and is easy to stick to.
✱ Who can use it?
Anyone who wants to prevent HIV and is at risk, including people facing barriers like stigma, low access to care, or trouble with daily pills. This is a more flexible, long-acting option.
✱ Why now?
Globally, HIV prevention still faces major gaps — especially in underserved communities, where access, awareness, & adherence to daily pills are low. This injection could help close that gap and reach more people who need protection.
✱ Who made it?
Gilead Sciences, the same company behind earlier HIV medicines. They’re aiming to expand access both in the U.S. and around the world.
✱ Global spotlight
Science magazine named it the “Breakthrough of the Year.” Experts say it could finally help end the HIV epidemic —if it’s made affordable.
✱ The price challenge
Right now, it costs over $28,218USD ≈ ₹24,44,617 INR, but researchers say it could be made for just $25–$40/year[≈ ₹2,166 INR - ₹3,466 INR per person per year]. Global health leaders are urging Gilead to lower the price.
✱ The bottom line
This new HIV prevention shot is a game-changer but only if people everywhere can get it. The science is ready. The next step is making it truly available for all.
https://www.reuters.com/business/healthcare-pharmaceuticals/us-fda-approves-gileads-twice-yearly-injection-hiv-prevention-2025-06-18
Doctor drug
-D-G